• Combination Therapy

    Regenetek’s Combination Stem Cell and Vascular Therapy

    read more
  • Regenerative Medicine

    ‎The Most Current Information Available from Leading Scientists and Clinical Trials World-wide

    read more
  • Patient Registry Software

    Application of Technology to Make Any Size of Study Self-Managing and Affordable

    read more
  • Neurodegenerative Disorders

    The Latest Updates on Diseases Treatable Through Regenerative Medicine

    read more
  • Topical
    Commentary

    Opinions from Regenetek and Leading Authorities in Regenerative Medicine

    read more

About: Doug Broeska

Doug Broeska is a PhD Medical Researcher and CEO of Regenetek Inc, a Canadian Biotech Research firm working with several hospitals and clinics world-wide to develop medical procedural protocols for neurodegenerative disease management.

Recent Posts by Doug Broeska

Introductory word

Hundreds of thousands of undocumented therapies occur in clinics world-wide each year under the label of ‘medical tourism’. Even if physicians in these clinics wanted to follow their patients, there has been no method of doing so. Until now. Regenetek Research recognizes that there is a high need for a method and a study design that provides proof of both safety and efficacy for new treatment interventions such as autologous stem cell therapies or unsanctioned vascular surgeries. These types of medical interventions present viable choices for patients beyond conventional drug therapies that only treat symptoms.


Deb O’Connell (click to watch)

MS Patient Under Study

Dr. Doug Broeska, PHD

Medical Researcher, Author

NEW WONDER DRUG FOR MS -TECFIDERA (BG-12)

The cost to an MS patient is between $60,000 in the US and $70,000 per year in Canada…and Biogen claims it’s effective for inhibiting MS symptoms…but they don’t quite know how it works…by their own admission (the medical research equivalent of throwing crap at the wall to see what sticks). Formerly it was only prescribed for symptoms of psoriasis. So how did dimethyl fumarate qualify to become the leading candidate for the treatment of MS?

With self-imposed funding caps for research, drug companies are performing big data searches on thousands of old clinical trials to look for unintended side-effects of molecules that can be interpreted to mean ‘efficacy’ for different diseases. Biogen found dimethylfumaric acid (BG-12), which demonstrated inhibition of immune cells by stimulating the expression of anti-inflammatory cytokines within the central nervous system, in previous trials. Theoretically, this old finding made it effective for the treatment of MS, and expensive-looking but short duration trials of only two years were performed to re-purpose and dress up a drug they already knew they were going to release for the treatment of Relapsing/Remitting MS. But where is Biogen’s conclusive proof that this relatively short period of clinical experimentation justifies the use of this method of disease treatment, and how solid is their data?

In 2009 when Paolo Zamboni came up with an original idea and clinical evidence to associate abnormal pathology in the jugular veins of MS patients to the disease process itself as a possible cause (chronic cerebrospinal venous insufficiency or CCSVI), it was a shot heard around the medical world. Could a simple two hour non-invasive medical procedure to expand neck veins really ‘cure’ a chronic, often fatal neurodegenerative disease and avoid a lifetime of misery for many MS patients? In 150 years of attempting to treat MS, could this pathophysiological abnormality and its relationship to the disease have been missed? After all, this Italian doctor Zamboni published a study that showed evidence of neurologic improvements and increased function after MS patients underwent the jugular vein-expanding procedure. And what do doctors really know about veins anyway? Not even vascular surgeons work in the veins very much. It all seemed plausible.

Towards a Patient Bill of Rights Part 2

We honor God when we use our intelligence to create for the greater good. That honor is of the highest order when we use everything that God has given us to create something that will improve or save lives. Improving the human condition is also the ultimate act of human kindness, and I believe that all humankind is good at its core. If we accept that human beings are essentially good, it also naturally implies that we understand the difference between good and evil, or right and wrong. Interestingly, even recent psychological experiments with babies have demonstrated that they know the difference between right and wrong at a very early age, long before socialization has occurred. Knowing the difference is part of the natural instinct of man. Doing wrong comes from man being put in desperate or artificial situations.

Towards a Patient Bill of Rights Pt 1

There is no known cure for neurodegenerative diseases such as MS, ALS, Parkinson’s disease or Alzheimer’s. And there is no drug in the conventional research pipeline that would allow patients stricken with any one of these diseases to hope for a cure in their lifetime. In trial after trial, pharma-based strategies have produced nothing more than symptomatic relief; none of the chemical-based drugs targeted at brain disease have been effective, and sometimes they have been highly unsafe with serious adverse side-effects. After 50 years of attempting to find some chemical element or compound that even suggests that such an approach can direct us towards a possible cure, isn’t it just possible that pharmacological-based medicinal substances cannot be effective by themselves in this regard?